US Healthcare Professionals

Not an actual patient.

Rely On Redemplo® Patient Support Program

For support, call 1-844-REDEMPLO (1-844-733-3675), Monday to Friday, 8 AM to 8 PM ET

We’re committed to providing your patients with the support they need

Living with Familial Chylomicronemia Syndrome (FCS) and beginning a new treatment can be challenging.
The Rely On Redemplo Patient Support Program is here to help with support services and resources from the start to guide your patients along their treatment journey with Redemplo®.

Support services​

We’re here to support your patients. The Rely On Redemplo Patient Support Program offers services and resources designed to support every stage of treatment.

Home delivery of Starter Kit
Expand Collapse

Starter Kit shipped directly to a patient’s home with clear, simple instructions and helpful resources to support their journey.

Pharmacist support
Expand Collapse

A clinical pharmacist is available to conduct additional injection training and provide patients pharmacy support in answering clinical questions regarding their Redemplo prescription.

For more information on these services, contact a Redemplo Care Coordinator at 1-844-REDEMPLO (1-844-733-3675), Monday to Friday, 8 AM to 8 PM ET

Indication & Important Safety Information
Expand Collapse

INDICATION

REDEMPLO® (plozasiran) is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

ADVERSE REACTIONS: Most common adverse reactions in REDEMPLO treated patients (incidence ≥10% of patients treated with REDEMPLO and > 5% more frequently than with placebo) are hyperglycemia, headache, nausea, and injection site reaction.

Please see full Prescribing Information for REDEMPLO.

Are you a healthcare professional in the US?

This site is intended for US Healthcare Professionals only. I am a licensed healthcare professional practicing in the United States.

No, I am not a healthcare professional

Are you sure you want to leave this site?

Continue